Dr. O'Sullivan Discusses the Future of HER2+ Breast Cancer Treatment

Ciara O'Sullivan, MB, BCh
Published: Monday, Nov 26, 2018



Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the future for HER2-positive breast cancer treatment.

O’Sullivan says that with progress, come questions, and the future of therapy for patients with HER2-positive breast cancer will focus on tailoring treatment to individual patients. Additionally, de-escalation and escalation will also be addressed and more fully developed as trials continue to read out. Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer in the last few years.

O’Sullivan adds that the findings anticipated for ongoing trials of HER2-directed therapy are liable to add significantly to the treatment landscape of the disease. Data with immunotherapy and CDK4/6 inhibitors are also anxiously awaited, as they have the potential to inform treatment decisions going forward.
SELECTED
LANGUAGE


Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the future for HER2-positive breast cancer treatment.

O’Sullivan says that with progress, come questions, and the future of therapy for patients with HER2-positive breast cancer will focus on tailoring treatment to individual patients. Additionally, de-escalation and escalation will also be addressed and more fully developed as trials continue to read out. Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer in the last few years.

O’Sullivan adds that the findings anticipated for ongoing trials of HER2-directed therapy are liable to add significantly to the treatment landscape of the disease. Data with immunotherapy and CDK4/6 inhibitors are also anxiously awaited, as they have the potential to inform treatment decisions going forward.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x